Search details
1.
Essential role for centromeric factors following p53 loss and oncogenic transformation.
Genes Dev
; 31(5): 463-480, 2017 03 01.
Article
in English
| MEDLINE | ID: mdl-28356341
2.
In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies.
Cell Mol Life Sci
; 71(20): 4007-26, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-25008045
3.
Fuzzy tandem repeats containing p53 response elements may define species-specific p53 target genes.
PLoS Genet
; 8(6): e1002731, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22761580
4.
Dynamic Histone H3 Incorporation Fuels Metastatic Progression.
Trends Mol Med
; 25(11): 933-935, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31624022
5.
[Moderation in all things: p53 deregulation, cancer and telomere syndromes]. / De la mesure en toute chose : dérégulation de p53, cancer et syndromes télomériques.
Med Sci (Paris)
; 29(12): 1071-3, 2013 Dec.
Article
in French
| MEDLINE | ID: mdl-24356130
6.
A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.
Nat Commun
; 9(1): 2371, 2018 06 18.
Article
in English
| MEDLINE | ID: mdl-29915258
7.
TCF12 is mutated in anaplastic oligodendroglioma.
Nat Commun
; 6: 7207, 2015 Jun 12.
Article
in English
| MEDLINE | ID: mdl-26068201
8.
Of mice and men: fuzzy tandem repeats and divergent p53 transcriptional repertoires.
Transcription
; 4(2): 67-71, 2013.
Article
in English
| MEDLINE | ID: mdl-23412358
9.
Mutant mice lacking the p53 C-terminal domain model telomere syndromes.
Cell Rep
; 3(6): 2046-58, 2013 Jun 27.
Article
in English
| MEDLINE | ID: mdl-23770245
10.
[The activation of p53 in tumors: a promising strategy against cancer]. / Réactivation de p53 dans les tumeurs: une stratégie antitumorale prometteuse.
Med Sci (Paris)
; 23(6-7): 565-7, 2007.
Article
in French
| MEDLINE | ID: mdl-17631822
Results
1 -
10
de 10
1
Next >
>>